

[1]Zwerling A., Behr M.A., Verma A., Brewer T.F., Menzies D., Pai M. The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. *PLoS Med.* 2011;8:e1001012.

[2]Martinon F., Krishnan S., Lenzen G., Magné R., Gomard E., Guillet J.-G., Lévy J.-P., Meulien P. Induction of Virus-Specific Cytotoxic T Lymphocytes in Vivo by Liposome-Entrapped mRNA. *Eur. J. Immunol.* 1993;23:1719–1722.

[3]Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA Vaccines—A New Era in Vaccinology. *Nat. Rev. Drug Discov.* 2018;17:261–279.

[4] Jirikowski G.F., Sanna P.P., Maciejewski-Lenoir D., Bloom F.E. Reversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA. *Science.* 1992;255:996–998.

[5]Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct Gene Transfer into Mouse Muscle in Vivo. *Science.* 1990;247:1465–1468.

[6]Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W. A Comprehensive Review of mRNA Vaccines. *Int J Mol Sci.* 2023 Jan 31;24(3):2700.

[7]Y. Li, X. Wang, D.M. Blau, M.T. Caballero, D.R. Feikin, C.J. Gill, S.A. Madhi, S.B. Omer, E.A.F. Simoes, H. Campbell, A.B. Pariente, D. Bardach, Q. Bassat, J.S. Casalegno, G. Chakhunashvili, N. Crawford, D. Danilenko, L.A.H. Do, M. Echavarria, A. Gentile, A. Gordon, T. Heikkinen, Q.S. Huang, S. Jullien, A. Krishnan, E.L. Lopez, J. Markic, A. Miral-Iglesias, H.C. Moore, J. Moyes, L. Mwananyanda, D.J. Nokes, F. Noordeen, E. Obodai, N. Palani, C. Romero, V. Salimi, A. Satav, E. Seo, Z. Shchomak, R. Singleton, K. Stolyarov, S.K. Stoszek, A. von Gottberg, D. Wurzel, L.M. Yoshida, C.F. Yung, H.J. Zar, N. Respiratory. Virus Global Epidemiology, H. Nair, R. investigators, Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*, 399 (10340) (2022), pp. 2047-2064

[8]D.K. Smith, S. Seales, C. Budzik. Respiratory syncytial virus bronchiolitis in children. *Am. Fam. Physician*, 95 (2) (2017), pp. 94-99

[9]C. Griffiths, S.J. Drews, D.J. Marchant. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. *Clin. Microbiol. Rev.*, 30 (1) (2017), pp. 277-319

[10]Nitika, Wei J., Hui A.M. The Development of mRNA Vaccines for Infectious Diseases: Recent Updates. *Infect. Drug Resist.* 2021;14:5271.

[11]N.I. Mazur, D. Higgins, M.C. Nunes, J.A. Melero, A.C. Langedijk, N. Horsley, U.J. Buchholz, P.J. Openshaw, J.S. McLellan, J.A. Englund, A. Mejias, R.A. Karron, E.A. Simoes, I. Knezevic, O. Ramilo, P.A. Piedra, H.Y. Chu, A.R. Falsey, H. Nair, L. Kragten-Tabatabaie, A. Greenough, E. Baraldi, N.G. Papadopoulos, J. Vekemans, F.P. Polack, M. Powell, A. Satav, E.E. Walsh, R.T. Stein, B.S. Graham, L.J. Bont, F. Respiratory. Syncytial virus network, the respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. *Lancet Infect. Dis.*, 18 (10) (2018), pp. e295-e311

[12] מידע אודות הניסוי

<https://classic.clinicaltrials.gov/ct2/show/NCT05127434>

[13]Watanabe T. 2013. Renal complications of seasonal and pandemic influenza A virus infections. *Eur J Pediatr* 172:15–22.

[14]Tsai JP, Baker AJ. 2013. Influenza-associated neurological complications. *Neurocrit Care* 18:118–130.

[15]Zangiabadian M, Nejadghaderi SA, Mirsaeidi M, Hajikhani B, Goudarzi M, Goudarzi H, Mardani M, Nasiri MJ. 2020. Protective effect of influenza vaccination on cardiovascular diseases: a systematic review and meta-analysis. *Sci Rep* 10:20656.

הודעת החברה [16] <https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/>

הודעת החברה [17] <https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention>

[18] Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. Edward E. Walsh, M.D., Gonzalo Pérez Marc, M.D., Agnieszka M. Zareba, M.D., Ph.D., Ann R. Falsey, M.D., Qin Jiang, M.S., Michael Patton, B.Sc., Fernando P. Polack, M.D., Conrado Llapur, M.D., Pablo A. Doreski, M.D., Kumar Ilangoan, M.D., Mika Rämetsä, M.D., Ph.D., Yasushi Fukushima, M.D., Ph.D., et al., for the RENOIR Clinical Trial Group. *April 20, 2023. N Engl J Med 2023; 388:1465-1477.

FDA [19] הודעת האישור של ה- <https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers>

FDA [20] הודעת האישור של ה- <https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants>

[21] Putri W, Muscatello DJ, Stockwell MS, Newall AT. 2018. Economic burden of seasonal influenza in the United States. Vaccine 36:3960–3966.

[22]Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, Sambhara S. Antiviral Approaches against Influenza Virus. Clin Microbiol Rev. 2023 Mar 23;36(1):e0004022.

[23]Centers for Disease Control and Prevention. 2021. Past seasons' vaccine effectiveness estimates. <https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html>. Retrieved 18 February 2022.

[24] הודעת החברה

<https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Interim-Phase-3-Safety-and-Immunogenicity-Results-for-mRNA-1010-a-Seasonal-Influenza-Vaccine-Candidate/default.aspx>

[25]Biondvax plunges on failed universal flu vaccine trial .<https://en.globes.co.il/en/article-biondvax-plunges-on-failed-universal-flu-vaccine-trial-1001346833>

[26] הודעת החברה

<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-3-study-mrna-based-influenza-vaccine>

[27] הודעת החברה <https://ir.novavax.com/press-releases/2021-09-23-Results-from-Novavax-NanoFlu-Influenza-Vaccine-Phase-3-Clinical-Trial-Published-in-The-Lancet-Infectious-Diseases>

[28]Leroux-Roels I, Willems P, Waerlop G, Janssens Y, Tourneur J, De Boever F, Bruhwylers J, Alhatemi A, Jacobs B, Nicolas F, Leroux-Roels G, Le Vert A. Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial. *Lancet Infect Dis*. 2023 Jul 27:S1473-3099(23)00351-1.

-ה מתוך אתר ה- [29]NIH <https://www.nih.gov/news-events/news-releases/clinical-trial-mrna-universal-influenza-vaccine-candidate-begins>

[30]<https://www.cnbc.com/2023/08/25/covid-vaccines-cdc-expects-new-shots-to-be-available-in-mid-september.html>

-ה מתוך אתר ה- [31]CDC <https://www.cdc.gov/cmvid/index.html>

[32]Pesch MH, Saunders NA, Abdelnabi S. Cytomegalovirus Infection in Pregnancy: Prevention, Presentation, Management and Neonatal Outcomes. *J Midwifery Womens Health*. 2021 May;66(3):397-402.

[33]Murata S, Oshima N, Iwasa T, Fukao Y, Sawata M. Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study. *Antibodies (Basel)*. 2023 Mar 10;12(1):22.

[34] מידע אודות הניסוי

<https://classic.clinicaltrials.gov/ct2/show/NCT05099965?recrs=abdf&type=Intr&cond=CMV&phase=014&draw=3&rank=21>

[35] Janssens E, Flamaing J, Vandermeulen C, Peetermans WE, Desmet S, De Munter P. The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value. Acta Clin Belg. 2023 Feb;78(1):78-86.

[36] הנחיות משרד הבריאות לחיסונים פנוימוקוקיים

https://www.gov.il/BlobFolder/policy/pneumo/he/files_publications_units_epidemiology_vaccine_guidelines_330_Pneumo.pdf

[37] Briles DE, Paton JC, Mukerji R, Swiatlo E, Crain MJ. Pneumococcal Vaccines. Microbiol Spectr. 2019 Nov;7.(6)

[38] הודעת החברה

<https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal>

[39] Cancer Stat Facts: Common Cancer Sites - NIH מתוך אתר ה-

<https://seer.cancer.gov/statfacts/html/common.html>

[40] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48.

[41] Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic Cancer: A Review of Current

Treatment and Novel Therapies. J Invest Surg.
2023 Dec 31;36(1):2129884

[42]Gavin P. Dunn. Cancer Vaccines: Preventive, Therapeutic, Personalized.

<https://www.cancerresearch.org/treatment-types/cancer-vaccines>

[43]Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Müller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Łuksza M, Cohen N, Tang L, Basturk O, Gönen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D'Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Türeci Ö, Greenbaum BD, Jarnagin WR, Drebin J, O'Reilly EM, Balachandran VP. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023 Jun;618(7963):144-150.

[44] הכתבה בנושא ב-Nature

<https://www.nature.com/articles/d41586-023-02171->

[X](#)

[45]Sarah E. Silk, Wilmina F. Kalinga, Ivanny M. Mtaka, ..., Simon J, Draper, Angela M. Minassian , Ally I. Olotur .uperior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. Med
11.8.23

[46] מתוך אתר ה-FDA. [https://www.fda.gov/vaccines-
blood-biologics/vaccines/anthrax](https://www.fda.gov/vaccines-blood-biologics/vaccines/anthrax)

[47] מתוך אתר ה-FDA.

[https://www.fda.gov/emergency-preparedness-and-
response/mcm-issues/ebola-preparedness-and-
response-updates-fda](https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/ebola-preparedness-and-response-updates-fda)